Sangamo Therapeutics Inc (SGMO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Sangamo Therapeutics Inc (SGMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012290
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:82
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biopharmaceutical company which focuses on the research and development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation and therapeutic genome editing. The company is developing genome editing and gene therapies for the treatment of genetically tractable diseases. Its product candidates targets the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), gaucher disease, fabry disease and many others. ZFPs based products can be used in human therapeutics, research reagents, plant agriculture, cell-line engineering and production of transgenic animals. The company has subsidiaries in the UK and the US. Sangamo is headquartered in Richmond, California, the US.

Sangamo Therapeutics Inc (SGMO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Sangamo BioSciences Enters Into Collaboration With CHDI Foundation 11
Licensing Agreements 12
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 12
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 13
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 15
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 16
Equity Offering 18
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 18
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 20
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 22
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 24
Sangamo BioSciences Completes Public Offering Of Common Stock For US$51.6 Million 26
Asset Transactions 28
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 28
Acquisition 29
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 29
Sangamo Therapeutics Inc – Key Competitors 31
Sangamo Therapeutics Inc – Key Employees 32
Sangamo Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Strategy And Business Planning 34
Nov 09, 2017: Sangamo Announces Plans For New Headquarters In Brisbane, California 34
Financial Announcements 35
Nov 09, 2017: Sangamo Therapeutics Reports Third Quarter 2017 Financial Results 35
Aug 09, 2017: Sangamo Therapeutics Reports Second Quarter 2017 Financial Results 37
May 10, 2017: Sangamo Therapeutics Reports First Quarter 2017 Financial Results 39
Feb 28, 2017: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results 40
Feb 27, 2017: Sangamo Therapeutics Announces Chief Financial Officer Succession 42
Oct 26, 2016: Sangamo BioSciences Reports Third Quarter 2016 Financial Results 43
Aug 03, 2016: Sangamo BioSciences Reports Second Quarter 2016 Financial Results 45
May 02, 2016: Sangamo BioSciences Reports First Quarter 2016 Financial Results 47
Feb 09, 2016: Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results 49
Corporate Communications 51
Jun 29, 2017: Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors 51
Apr 25, 2017: Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors 52
Dec 01, 2016: Sangamo BioSciences announces management changes 53
Dec 01, 2016: Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities 54
Jun 01, 2016: Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor 55
Product News 57
11/17/2016: Genetically Engineered T Cells Render HIV Harpoon Powerless 57
10/17/2017: Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy 59
06/20/2016: Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II 60
02/08/2016: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I 62
Product Approvals 64
Jun 07, 2017: Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency 64
May 16, 2017: Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 65
May 04, 2017: Sangamo Therapeutics Announces Orphan Drug Designation for SB-525 cDNA Gene Therapy for Hemophilia A 66
Feb 27, 2017: Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I 67
Jan 11, 2017: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I 68
Jan 05, 2017: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A 69
Sep 06, 2016: Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing 70
Clinical Trials 71
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-318 at The 13th Annual WORLDSymposium Meeting 71
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-913 at The 13th Annual WORLDSymposium Meeting 72
Dec 05, 2016: Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting 73
Jul 26, 2016: Sangamo BioSciences Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A 74
May 09, 2016: Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic Programs In Multiple Presentations At Annual Meeting of the American Society of Gene and Cell Therapy 75
Feb 24, 2016: Sangamo BioSciences Presents Phase II Immunological Data from SB-728-T ZFP Therapeutic HIV Program at CROI 2016 77
Other Significant Developments 79
Jan 06, 2017: Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies 79
Nov 30, 2016: Sangamo’s Genome Editing Program for Hemoglobinopathies to Transfer to Biogen’s Spin-Off Bioverativ 80
Jan 11, 2016: Sangamo BioSciences Highlights 2016 Catalysts at the 34th Annual J.P. Morgan Healthcare Conference 81
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82

List of Tables
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Sangamo Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sangamo BioSciences Enters Into Collaboration With CHDI Foundation 11
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 12
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 13
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 15
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 16
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 18
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 20
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 22
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 24
Sangamo BioSciences Completes Public Offering Of Common Stock For US$51.6 Million 26
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 28
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 29
Sangamo Therapeutics Inc, Key Competitors 31
Sangamo Therapeutics Inc, Key Employees 32
Sangamo Therapeutics Inc, Subsidiaries 33

★海外企業調査レポート[Sangamo Therapeutics Inc (SGMO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RATP Group:企業の戦略・SWOT・財務情報
    RATP Group - Strategy, SWOT and Corporate Finance Report Summary RATP Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Karachaganak Petroleum Operating BV:企業の戦略的SWOT分析
    Karachaganak Petroleum Operating BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Westar Energy Inc (WR)-エネルギー分野:企業M&A・提携分析
    Summary Westar Energy, Inc. (Westar Energy) is a vertically integrated energy utility that generates, transmits and distributes electricity. The company owns and operates a generation portfolio of coal-fired, nuclear, natural gas-based, renewable and diesel-based power plants. It also procures elect …
  • Lunaphore Technologies SA:医療機器:M&Aディール及び事業提携情報
    Summary Lunaphore Technologies SA (Lunaphore) is a medical device company that develops tissue processing solutions for inmmunohistochemistry. The company builds tumor analysis and classification platforms based on a microfluidic technologies. It offers FFeX, a fast fluidic exchange technology that …
  • Ushdev International Limited (511736)-エネルギー分野:企業M&A・提携分析
    Summary Ushdev International Limited (Ushdev) is a trading company primarily focusing on ferrous and non-ferrous metals. It trades various ferrous and non-ferrous metals including raw materials such as metallurgical coal and coke, steel crap, iron ore-lumps, pi iron, sponge iron, fines, copper scrap …
  • Neurim Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Neurim Pharmaceuticals Ltd (Neurim) is a drug discovery company that develops drugs for central nervous system diseases.The company's product line includes circadin that is used in insomnia treatment. Neurim offers paediatric prolonged-release melatonin, piromelatine, NEU-P12 and NEU-240. Th …
  • Scatec Solar ASA (SSO)-エネルギー分野:企業M&A・提携分析
    Summary Scatec Solar ASA (Scatec Solar) is an integrated independent producer of solar power that develops, builds, owns and operates solar power plants. It conducts project origination and development, project financing, design and engineering, procurement and construction management, operation and …
  • Impol Seval A.D. Sevojno
    Impol Seval A.D. Sevojno - Strategy, SWOT and Corporate Finance Report Summary Impol Seval A.D. Sevojno - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CJ ENM Co., Ltd. (035760):企業の財務・戦略的SWOT分析
    CJ ENM Co., Ltd. (035760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Koc Holding AS:企業の戦略・SWOT・財務情報
    Koc Holding AS - Strategy, SWOT and Corporate Finance Report Summary Koc Holding AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • NETGEAR Inc (NTGR):企業の財務・戦略的SWOT分析
    NETGEAR Inc (NTGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Petropavlovsk Plc
    Petropavlovsk Plc - Strategy, SWOT and Corporate Finance Report Summary Petropavlovsk Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Tokio Marine Holdings, Inc.:戦略・SWOT・企業財務分析
    Tokio Marine Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tokio Marine Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • John Menzies Plc
    John Menzies Plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Myriad Genetics, Inc.:企業の戦略・SWOT・財務分析
    Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Agricultural Bank of China Ltd:企業の戦略・SWOT・財務情報
    Agricultural Bank of China Ltd - Strategy, SWOT and Corporate Finance Report Summary Agricultural Bank of China Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Recro Pharma Inc (REPH):企業の財務・戦略的SWOT分析
    Recro Pharma Inc (REPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Sibur Holding:企業の戦略的SWOT分析
    Sibur Holding - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • TiGenix NV (TIG):企業の財務・戦略的SWOT分析
    Summary TiGenix NV (TiGenix), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products. The company exploits the anti-inflammatory properties of stem cells to develop novel therapies. It offers products such as AlloCSC-0 …
  • Spectrum Brands Holdings Inc (SPB):企業の財務・戦略的SWOT分析
    Spectrum Brands Holdings Inc (SPB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆